Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
571099,"Roche TCRC, Inc.",NY,100000000166,3000.00,07/28/2014,"Cash or cash equivalent",207418022,"NonCovered Product","","PDE10 INHIB. IN SCHIZOPHRENIA","",""
571099,"Otsuka Pharmaceutical Development & Commercialization, Inc.",NJ,100000010725,300.00,03/21/2014,"Cash or cash equivalent",216063236,"","","Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole OPC-14597 as Maintenance Treatment in Bipolar I Patients",https://www.clinicaltrials.gov/show/NCT01567527,""
571099,"Roche TCRC, Inc.",NY,100000000166,185.63,07/15/2014,"Cash or cash equivalent",207427612,"NonCovered Product","","PDE10 INHIB. IN SCHIZOPHRENIA","",""
